Mycophenolate Mofetil Clinical Trials
40 recruitingDrug
Phase 230Phase 111Phase 32Phase 42Not Applicable1
Showing 1–20 of 40 trials
Recruiting
Phase 2
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+7 more
Fred Hutchinson Cancer Center54 enrolled1 locationNCT06013423
Recruiting
Phase 1Phase 2
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Hematopoietic and Lymphoid System Neoplasm
M.D. Anderson Cancer Center25 enrolled1 locationNCT04022239
Recruiting
Phase 2
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Hematologic Malignancies
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07359859
Recruiting
Phase 2
Allo HSCT Using RIC and PTCy for Hematological Diseases
Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+15 more
Masonic Cancer Center, University of Minnesota56 enrolled1 locationNCT05805605
Recruiting
Phase 1
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
Acute Myeloid Leukemia
OHSU Knight Cancer Institute40 enrolled1 locationNCT07548983
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Lupus Nephritis
Hoffmann-La Roche40 enrolled42 locationsNCT05039619
Recruiting
Phase 1
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
Acute Myeloid LeukemiaMyelodysplastic SyndromeGraft-Versus-Host Disease
City of Hope Medical Center15 enrolled1 locationNCT06996119
Recruiting
Phase 1
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Hematologic NeoplasmsHematologic Malignancies
National Cancer Institute (NCI)155 enrolled1 locationNCT07162038
Recruiting
Phase 3
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Renal Allograft Recipients
Bristol-Myers Squibb102 enrolled38 locationsNCT04877288
Recruiting
Phase 1Phase 2
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center75 enrolled1 locationNCT03128034
Recruiting
Phase 1Phase 2
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Phase 1Phase 2
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Non-Malignant Neoplasm
Fred Hutchinson Cancer Center40 enrolled1 locationNCT04083183
Recruiting
Phase 1Phase 2
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Hematologic Neoplasms
National Cancer Institute (NCI)320 enrolled2 locationsNCT04959175
Recruiting
Phase 2
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Severe Aplastic AnemiaAcquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell Aplasia+1 more
Masonic Cancer Center, University of Minnesota60 enrolled1 locationNCT06412497
Recruiting
Phase 2
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Sickle Cell DiseaseThalassemiaThalassemia (beta)
Memorial Sloan Kettering Cancer Center24 enrolled6 locationsNCT05736419
Recruiting
Phase 2
Allo HSCT for High Risk Hemoglobinopathies
Sickle Cell DiseaseHemoglobinopathiesGraft Failure
Masonic Cancer Center, University of Minnesota62 enrolled1 locationNCT06872333
Recruiting
Phase 2
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 2
Advancing Transplantation Outcomes in Children
Kidney Transplant
National Institute of Allergy and Infectious Diseases (NIAID)200 enrolled20 locationsNCT06055608
Recruiting
Phase 2
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
AML
M.D. Anderson Cancer Center80 enrolled1 locationNCT06973668
Recruiting
Phase 2
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Acute Lymphoblastic LeukemiaHodgkin LymphomaNon-Hodgkin Lymphoma+5 more
Memorial Sloan Kettering Cancer Center71 enrolled1 locationNCT07566377